Oct 02, 2019 / 09:20PM GMT
Charles Duncan - Cantor Fitzgerald - Analyst
Okay, I think we will get started. So good morning. Day one of the fifth annual Cantor Fitzgerald global healthcare conference. I am Charles Duncan. I am a senior biotechnology analyst and I'm a managing director for the firm.
Team Duncan joined Cantor about 14 months ago and we have established coverage on approximately 30 companies. And very excited to host 24 of them today or this week for fireside chats.
And so not to take too much time, I wanted to introduce the next management team that will be presenting. And I'm excited to introduce you to the management from Voyager Therapeutics. Voyager is a gene therapy company focused on neurological disorders. And we cover a lot of neuro innovators and this is arguably one of the only or the only gene therapy company in the space that we thought made sense for us to cover. And so Voyager, ticker symbol VYGO. We rate the stock overweight rating. We have established a $31 price target.
But I'm excited to introduce Ms. Allison Dorval, who is the Company's Chief Financial Officer who is with
Voyager Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Mar 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers